FemPulse, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today the successful close of its Series D financing round.
Read MoreIn the News
. . . . .
In the News
. . . . .
FemPulse, a bioelectronic medical technology company with first application overactive bladder (OAB), announced today the successful close of its Series D financing round.
Read MoreFemPulse announced today that the company’s pivotal clinical study was selected for presentation at the American Urological Association (AUA) annual conference in Washington, DC on Friday, May 15, 2026.
Read MoreFemPulse announced today that the company's two recent usability studies will be presented at the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) annual conference on February 27, 2026.
Read MoreFemPulse announced today that medical AI Expert Wido Menhardt, PhD has joined the company's Scientific Advisory Board.
Read MoreFemPulse announced today Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin its EVANESCE II pivotal clinical trial in female patients suffering from overactive bladder (OAB).
Read MoreFemPulse announced today the closing of its Series C financing. The company’s existing investors participated in the round, as well as two new large investors.
Read MoreFemPulse Corporation today announced the issuance of a European patent covering its vaginally-inserted nerve stimulation technology.
Read MoreFemPulse Corporation today announced that Robert Taub will join the Company’s board of directors as the representative of the Series B investors.
Read MoreFemPulse featured in Daily Mail article: Could a doughnut-shaped nerve zapper cure overactive bladders in women?
Read More